Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN – Research Report), Crinetics Pharmaceuticals (CRNX – Research Report) and Alignment Healthcare (ALHC – Research Report).
Amgen (AMGN)
Robert W. Baird analyst Brian Skorney maintained a Sell rating on Amgen on May 3 and set a price target of $215.00. The company’s shares closed last Tuesday at $300.30.
According to TipRanks.com, Skorney is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen with a $321.29 average price target.
See the top stocks recommended by analysts >>
Crinetics Pharmaceuticals (CRNX)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Crinetics Pharmaceuticals on May 6 and set a price target of $52.00. The company’s shares closed last Tuesday at $47.66, close to its 52-week high of $49.58.
According to TipRanks.com, Schwartz is a 2-star analyst with an average return of
Crinetics Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $62.33, which is a 30.3% upside from current levels. In a report released yesterday, Piper Sandler also assigned a Buy rating to the stock with a $97.00 price target.
Alignment Healthcare (ALHC)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on Alignment Healthcare on May 5 and set a price target of $9.00. The company’s shares closed last Tuesday at $6.87.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alignment Healthcare with a $7.67 average price target, implying a 12.8% upside from current levels. In a report issued on April 23, Stifel Nicolaus also maintained a Buy rating on the stock with a $9.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
- Fly Insider: Theravance Bio, Amgen among week’s notable insider trades
- CytomX Therapeutics upgraded to Buy from Hold at Jefferies
- Amgen price target raised to $325 from $315 at BofA
- Amgen price target lowered to $328 from $332 at RBC Capital
- Early notable gainers among liquid option names on May 3rd
